Previous 10 | Next 10 |
Royalty Pharma plc (RPRX) Q2 2021 Earnings Conference Call August 11, 2021, 8:00 am ET Company Participants George Grofik - SVP & Head, IR & Communications Pablo Legorreta - Founder & CEO Jim Reddoch - EVP, Co-Head Research & Investments & CSO Marshall Urist - EVP & Co...
The following slide deck was published by Royalty Pharma plc in conjunction with their 2021 Q2 earnings call. For further details see: Royalty Pharma plc 2021 Q2 - Results - Earnings Call Presentation
Strong growth in net cash provided by operating activities (GAAP) and Adjusted Cash Flow ( 2) Announced transactions of up to $2.8 billion in 2021, including $2.1 billion * in upfront payments Increased 2021 guidance: Adjusted Cash Receipts ( ...
NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter of 2021 financial results on Wednesday, August 11, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webca...
NEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share. The dividend will be paid on September 15, 2021, to shareholders of record ...
Royalty Pharma (RPRX) priced an offering of $1.3B of senior unsecured notes.The company priced $600M of 2.15% senior notes due 2031 (the Social Bonds) and $700M of 3.35% senior notes due 2051.The company intends to use an amount equal to the net proceeds from the Social Bonds to finance or re...
Social Bond issuance underscores Royalty Pharma’s strong commitment to ESG Supports United Nations Sustainable Development Goals NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of ...
Zhanna Hapanovich/iStock via Getty Images Concerned over high premiums of targets, the large-cap pharmaceutical companies have taken a backseat in acquisitions this year as they focused on repayment of debt accumulated due to previous deals. Meanwhile, with the need to sustain the long-term g...
gerenme/iStock via Getty Images The advancements in treatments for Alzheimer’s disease have spurred gains among large-cap pharmaceutical companies in the first half of 2021. Eisai ([[ESALY]] -0.9%) and Eli Lilly ([[LLY]] +0.7%) are among the five leading gainers in the pharmaceutical s...
Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...